Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 19/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 11/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100770 | 0.90 | MGLL (0.54) | MGLLABHD6PLA2G7LMNAMAPK1 | |
| SCHEMBL15100775 | 0.90 | MGLL (0.61) | MGLLABHD6PLA2G7 | |
| SCHEMBL18623641 | 0.84 | ATM (0.46) | LMNAMAPK1 | |
| SCHEMBL16744508 | 0.83 | SCD5 (0.52) | LMNAMAPK1 | |
| SCHEMBL15094311 | 0.79 | MGLL (0.79) | MGLLABHD6PLA2G7 | |
| SCHEMBL16577089 | 0.79 | LMNA (0.48) | MGLLLMNAMAPK1CYP2D6 | |
| SCHEMBL18634191 | 0.77 | MAPT (0.53) | LMNAMAPK1 | |
| SCHEMBL20778509 | 0.75 | MGLL (0.57) | MGLL | |
| SCHEMBL20778407 | 0.75 | MGLL (0.53) | MGLL | |
| SCHEMBL18623647 | 0.75 | MGLL (0.44) | MGLLABHD6PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | claimed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-9957242-B2 | Carbamate compounds and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | disclosed |
| US-9487495-B2 | Carbamate compounds and of making and using same | THE SCRIPTS RESEARCH INSTITUTE (US) | 2016-11-08 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | MGLL 14/4885ABHD6 1/4885PLA2G7 277/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | MGLL 54/4885ABHD6 1/4885PLA2G7 195/4885 |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABHD6, ABHD16A, PRMT6 | MGLL 16/4885ABHD6 1/4885PLA2G7 320/4885 |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | MGLL 14/4885ABHD6 1/4885PLA2G7 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.